Literature DB >> 2125989

Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay.

Y Fujiwara1, K Kasahara, Y Sugimoto, K Nishio, T Ohmori, N Saijo.   

Abstract

Using a gel mobility shift assay, we have identified proteins, in the nuclear extracts of a human lung cancer cell line, that recognize cis-diamminedichloroplatinum(II) (cis-DDP, CDDP)-modified DNA. A 158-base-pair double-stranded DNA fragment, derived from pBR322 plasmid DNA, was modified by either CDDP, tetrachloro(dl-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) or trans-DDP (the stereoisomer of CDDP and clinically ineffective). These platinum drug-modified probes were incubated with nuclear extracts and analyzed by gel mobility shift assay. Proteins in the extracts selectively recognized the clinically active platinum-modified DNA fragment. No binding to the trans-DDP-modified DNA fragment was observed. These proteins may play a role in the cytotoxicity or in a DNA repair process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2125989      PMCID: PMC5918002          DOI: 10.1111/j.1349-7006.1990.tb02680.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


cis‐diamminedichloroplatinum(II) tetrachloro(dl‐trans)‐1,2‐diaminocyclohexaneplatinum (IV) unlabeled CDDP‐modified salmon testis DNA unlabeled, unmodified salmon testis DNA
  12 in total

Review 1.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

Authors:  P A Andrews; S B Howell
Journal:  Cancer Cells       Date:  1990-02

2.  A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes.

Authors:  H Singh; R Sen; D Baltimore; P A Sharp
Journal:  Nature       Date:  1986 Jan 9-15       Impact factor: 49.962

3.  Molecular cloning of an enhancer binding protein: isolation by screening of an expression library with a recognition site DNA.

Authors:  H Singh; J H LeBowitz; A S Baldwin; P A Sharp
Journal:  Cell       Date:  1988-02-12       Impact factor: 41.582

4.  Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

Authors:  A Eastman; N Schulte
Journal:  Biochemistry       Date:  1988-06-28       Impact factor: 3.162

5.  A small-scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing.

Authors:  K A Lee; A Bindereif; M R Green
Journal:  Gene Anal Tech       Date:  1988 Mar-Apr

6.  Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II)

Authors:  J H Toney; B A Donahue; P J Kellett; S L Bruhn; J M Essigmann; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.

Authors:  M Bungo; Y Fujiwara; K Kasahara; K Nakagawa; Y Ohe; Y Sasaki; S Irino; N Saijo
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

8.  Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA.

Authors:  G Chu; E Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

9.  Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).

Authors:  H Masuda; T Tanaka; H Matsuda; I Kusaba
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

10.  Determinants of drug response in a cisplatin-resistant human lung cancer cell line.

Authors:  Y Fujiwara; Y Sugimoto; K Kasahara; M Bungo; M Yamakido; K D Tew; N Saijo
Journal:  Jpn J Cancer Res       Date:  1990-05
View more
  2 in total

Review 1.  7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.

Authors:  N Saijo; K Nishio; N Kubota; F Kanzawa; T Shinkai; A Karato; Y Sasaki; K Eguchi; T Tamura; Y Ohe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.

Authors:  H Arioka; K Nishio; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; H Kurokawa; H Yokote; S Abe; N Saijo
Journal:  Jpn J Cancer Res       Date:  1999-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.